Galien week of innovation
BIOTECH - Tuesday Oct. 25
11 AM - 12 PM ET
What is the underlying science behind clinical progress in therapies that promise a genetics-based cure for devastating rare diseases and how will this contribute to the next wave of innovations? What are the implications for continued patient access to these high-cost, high-touch treatments – does the ROI calculation for rare diseases still add up?
Director, Product Marketing, H1
Vice President of Corporate Development & Strategy, argenx
Christine Clemson, PhD MSCI
Senior Vice President, Global Head of Medical Affairs, Albireo Pharma, Inc.
President, CEO, Director, ChemoCentryx
SVP, Chief Medical Officer,
Novartis Gene Therapies
Filip Van den Wyngaert, MSc
Global Head for TTP,
12 PM - 1 PM ET
Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to treatment, particularly in solid tumors?
Michael Ringel, PhD
Managing Director and Senior Partner,
Global Leader, Growth & Innovation Analytics,
BCG Boston Consulting Group
Senior VP, External Innovation,
Senior Vice President, Early Clinical Development, Oncology/Hematology and Cell Therapy,
Bristol Myers Squibb
Gerold Meinhardt, MD, PhD
Vice President, Asset & Portfolio Management,
Robert Iannone, MD, MSCE
Executive Vice President, Global Head of Research and Development, Jazz Pharmaceuticals
1 PM - 2 PM ET
Given that many chronic diseases have an infectious origin, what learnings can be had by the most recent innovations in vaccine development technology in raising the bar on innovations to address the huge unmet need against conditions that kill millions?
Director, Product Marketing,
Ulrike K Buchwald, MD Dr. med MS
Executive Director, Global Clinical Development, Vaccine, Merck & Co., Inc.
Theresa Podrebarac, MD, MSc
Senior Vice President, Clinical Development,
David E. Anderson
Chief Scientific Officer,
VBI Vaccines, Inc.
Jaya L. Tiwari
Vice President Clinical & Regulatory Affairs USA,